Glooko mHealth Advantage Study

Completed · Not applicable

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko

Key facts

Study ID

NCT02974816

Run by

Glooko

People needed

197

Starts

2017-05-15

Expected to finish

2020-04-17

Last updated by the study team

2021-06-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act (HIPAA) or other privacy authorization prior to any participation in study.
• Subject has self-reported type 2 diabetes.
• Subject has HbA1c ≥ 7.5% and ≤ 12.5% measured within 30 days of screening visit.
• Subject is on a stable diabetes therapeutic regimen of two or more diabetic medications (e.g., metformin plus one other antihyperglycemic agent) and/or insulin therapy for at least 2 months before screening visit. Dose changes or adjustments made within 2 months is acceptable as long as the patient has been on the medication regimen for 2 months or longer.
• Subject is ≥ 18 and ≤ 75 years of age.
• Subject is a male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
• If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study):
• Condoms, sponge, diaphragm, or intrauterine device;
• Oral or parenteral contraceptives for 3 months prior to screening visit;
• Vasectomized partner;
• Total abstinence from sexual intercourse
• Subject is able to speak, read and write in English
• Subject has a Glooko compatible smartphone/device with an active data plan or access to Wi-Fi and downloaded at least one mobile application on their phone on their own.
• Subject has performed self-monitoring of blood glucose at least five (5) times within two (2) weeks prior to screening visit.

You may not qualify if…

• Subject has type 1 diabetes.
• Subject has advanced disease (physical or psychological) that would prevent them from being able to comply with study tasks and considered exclusionary by the study physicians.
• Subject has been on medication or therapy within the last 2 months that severely affects blood glucose levels (e.g. corticosteroids).
• Subject has visual impairment which severely limits his/her ability to see or use the mobile application.
• Subject is a participant in another clinical study that has not been approved as a concomitant study by Glooko.

Where it is running

• John Muir Physician Network Clinical Research Center — Concord, California, United States
• Sutter Health — Elk Grove, California, United States
• Scripps Whittier Diabetes Institute — San Diego, California, United States
• Billings Clinic — Billings, Montana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.